Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
作者信息
Cortes Jorge, Tsimberidou Apostolia M, Alvarez Ricardo, Thomas Deborah, Beran Miloslav, Kantarjian Hagop, Estey Elihu, Giles Francis J
机构信息
Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA.
出版信息
Cancer Chemother Pharmacol. 2002 Dec;50(6):497-500. doi: 10.1007/s00280-002-0539-y. Epub 2002 Oct 22.
PURPOSE
Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML.
METHODS
MTA consisted of Mylotarg 9 mg/m(2) intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m(2) over 2 h i.v. on days 1 through 5, and topotecan 1.25 mg/m(2) by continuous infusion i.v. on days 1 through 5.
RESULTS
A group of 17 patients (9 primary resistant, 8 relapsed) with AML or advanced myelodysplastic syndrome (MDS) received 20 courses of MTA. The median age of the patients was 55 years (20-70 years). Two patients (12%) achieved complete remission. The median overall survival was 8.2 weeks. Five patients (29%) developed grade 3/4 hepatic transaminitis, including one patient (6%) who died with hepatic venoocclusive disease.
CONCLUSIONS
MTA was moderately effective and associated with significant toxicity in patients with refractory AML.
Zotero 插件